Dyno Therapeutics is reshaping the gene therapy landscape with AI-powered AAV vectors

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.
-
Industry
-
Milestones
- Lux investment: 2021
-
Founders
- Eric Kelsic
- Alan Crane
- Sam Simai
- Adrian Veres
- George Church
- Tomas Bjorklund
LUX Partners
-
Latest Tweets
- Come join our first Agile in Biotech MeetUp - a forum where those of us interested in experimenting with Agile appr… https://t.co/VU6AeMkFgL
- #BIO2022 is almost here! Meet up with our team during the conference to learn more about our machine-guided approac… https://t.co/oVuqKrkWsC
- Reminder: Our team is hosting a symposium tomorrow from 12-1:30 PM in Room 202 on how we are transforming the gene… https://t.co/pDbAbDZAmw